These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 29469551)

  • 1. Don’t Try This at Home: the FDA’s Restrictive Regulation of Home Testing Devices.
    Baird S
    Duke Law J; 2017 Nov; 67(2):383-426. PubMed ID: 29469551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The regulation of home diagnostic tests for genetic disorders: can the FDA deny a premarket application on the basis of the device's social impacts?
    Kerouac JD
    J Biolaw Bus; 2002; 5(1):34-43. PubMed ID: 12751500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic gatekeepers: regulating direct-to-consumer genomic services in an era of participatory medicine.
    Palmer JE
    Food Drug Law J; 2012; 67(4):475-524, iii. PubMed ID: 24640618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
    Roller ST; Pippins RR; Ngai JW
    Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct-to-Consumer Genetic Testing: The Implications of the US FDA's First Marketing Authorization for BRCA Mutation Testing.
    Gill J; Obley AJ; Prasad V
    JAMA; 2018 Jun; 319(23):2377-2378. PubMed ID: 29800087
    [No Abstract]   [Full Text] [Related]  

  • 6. “Better Not to Know?”: Justifiable Limits on the Right to Information in the Realm of DTC Genetic Testing. An Analysis of the European and Spanish Legal Framework.
    Martínez Otero JM
    Eur J Health Law; 2017 Apr; 24(2):175-97. PubMed ID: 29210260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
    Basile EM; Tolomeo D; Gluck E
    Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 23andMe: a new two-sided data-banking market model.
    Stoeklé HC; Mamzer-Bruneel MF; Vogt G; Hervé C
    BMC Med Ethics; 2016 Mar; 17():19. PubMed ID: 27059184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reflections on the US FDA's Warning on Direct-to-Consumer Genetic Testing.
    Yim SH; Chung YJ
    Genomics Inform; 2014 Dec; 12(4):151-5. PubMed ID: 25705152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA halts 23andMe personal genetic tests. What might this mean for the future of direct-to-consumer testing?
    Darnovsky M; Cussins J
    MLO Med Lab Obs; 2014 Mar; 46(3):33. PubMed ID: 24696953
    [No Abstract]   [Full Text] [Related]  

  • 11. The U. S. Food and Drug Administration's role in contact lens development and safety.
    Saviola JF; Hilmantel G; Rosenthal AR
    Eye Contact Lens; 2003 Jan; 29(1 Suppl):S160-5; discussion S166, S192-4. PubMed ID: 12772757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Price, performance, and the FDA approval process: the example of home HIV testing.
    Paltiel AD; Pollack HA
    Med Decis Making; 2010; 30(2):217-23. PubMed ID: 19429837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct-to-consumer genetic testing: Perspectives on its value in healthcare.
    Delaney SK; Christman MF
    Clin Pharmacol Ther; 2016 Feb; 99(2):146-8. PubMed ID: 26517013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct-to-Consumer Genetic Testing: Finding a Clear Path Forward.
    Seward B
    Ther Innov Regul Sci; 2018 Jul; 52(4):482-488. PubMed ID: 29714553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA's perspectives on cardiovascular devices.
    Chen EA; Patel-Raman SM; O'Callaghan K; Hillebrenner MG
    J Cardiovasc Transl Res; 2009 Jun; 2(2):143-6. PubMed ID: 20559979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should preemption apply in a pharmaceutical context? An analysis of the preemption debate and what regulatory compliance statutes contribute to the discussion.
    Surprenant JA
    Fordham Law Rev; 2008 Oct; 77(1):327-63. PubMed ID: 18982554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmaceuticals and Medical Devices: FDA Oversight.
    Berry MD; White RS;
    Issue Brief Health Policy Track Serv; 2016 Dec; 2016():1-59. PubMed ID: 28252888
    [No Abstract]   [Full Text] [Related]  

  • 18. The FDA's perspective on clinical laboratory devices. The premarket review and evaluation process.
    Aziz KJ; Sliva CA; Gutman SI
    Am Clin Lab; 1996; 15(1):10-1. PubMed ID: 10163487
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA'S food ingredient approval process: Safety assurance based on scientific assessment.
    Rulis AM; Levitt JA
    Regul Toxicol Pharmacol; 2009 Feb; 53(1):20-31. PubMed ID: 18983884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evolution of substantial equivalence in FDA's premarket review of medical devices.
    Goldberger BA
    Food Drug Law J; 2001; 56(3):317-37. PubMed ID: 11944642
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.